Good try shorts, LOL.
Imo. another weak attempt by colluding shorts, but not working because the longs are strong here and know how they twist information. Shorts are scared. Remember bad stocks don't need to be bashed only good ones!
Others should post this to other boards. Many still do not know this company.
See ihub posts 60343 and 60408 ! Google ihub avxl and then scroll down and put in post numbers.
VALENCIA, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host
an analyst call for the investment community to learn about the company's general commercialization strategy in the US for
Afrezza® (insulin human) Inhalation Powder. MannKind has recently assumed responsibility for the worldwide development
and commercialization of Afrezza from Sanofi and will begin to distribute Afrezza in the third quarter. Until that time, Sanofi
will continue to distribute Afrezza from its existing inventory of product.
To participate in the live call by telephone, please dial (888) 224-7957 or (303) 223-4394 and use the participant passcode:
Time slots have been updated for the May symposium.
Dr. Missling will be speaking from 15.40-16.10, a hefty 30 minutes. That should be more than enough time to go over lots and lots of data!
See company web page for all news releases. Human trials just extended drug for 2 years due to amazing results. Patients and caregivers asked for the addition extention from 26 weeks to 52 weeks now 2 years!!
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications, including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia, and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.
See Feb 8th news!
Feb 8th news !
Feb 8th news.